Buy ARA-290 Peptide Online – Premium ARA-290 Research Peptide

ARA-290 peptide, also known as cibinetide, ARA 290, or pyroglutamate helix B surface peptide (pHBSP), is an investigational 11-amino-acid peptide derived from the three-dimensional structure of erythropoietin (EPO). ARA-290 has attracted substantial scientific interest because researchers have investigated its interaction with the innate repair receptor (IRR), a receptor complex associated with tissue-protection, cellular signaling, and repair responses following injury or inflammation. At Buy Pure Peptide, ARA-290 is supplied strictly for laboratory, analytical, and scientific research purposes. It is not presented as an approved medication or as a treatment for neuropathy, diabetes, inflammation, nerve injury, or any other medical condition. Researchers interested in related compounds can also explore our GHRP-2 Acetate, Adipotide, Gonadorelin Acetate 2mg, HGH 191AA 10IU, Vitamin B12 10ml, and 5-Amino-1MQ 5mg × 10 Vials.

What Is ARA-290?

ARA-290 is a synthetic peptide modeled on the helix-B region of erythropoietin. Unlike conventional erythropoietin signaling through the homodimeric EPO receptor, ARA-290 was developed to selectively activate the innate repair receptor, a receptor complex involving the erythropoietin receptor and β-common receptor (CD131). This mechanism has made ARA-290 an important research tool for investigating the relationship between:

• Tissue injury
• Neuroinflammation
• Cellular protection
• Peripheral nerve biology
• Immune signaling
• Tissue repair
• Peptide-receptor interactions

A 2024 review continued to identify ARA-290 as an important experimental EPO-derived peptide in peripheral nerve research while noting limitations such as its short half-life. Read the 2024 ARA-290 Peripheral Nerve Research Review on PubMed

ARA-290 and the Innate Repair Receptor

One of the most important reasons researchers study ARA-290 is its relationship with the innate repair receptor (IRR). The IRR is described as a heteromeric receptor involving the erythropoietin receptor and β-common receptor. Research suggests that this receptor can become more prominent following tissue stress or injury and may participate in signaling associated with protection and repair. ARA-290 was developed to activate this pathway without producing the classical erythropoietic effects associated with conventional EPO. This provides researchers with a useful experimental model for studying tissue-protection mechanisms independently from erythropoiesis.

ARA-290 and Neurobiology Research

ARA-290 has been extensively investigated in experimental neuroscience and peripheral nerve research. Preclinical studies have examined the peptide in models of peripheral nerve injury and neuropathic pain. In animal experiments, researchers observed reductions in mechanical and cold allodynia alongside changes in spinal microglial responses. These findings have made ARA-290 relevant to laboratory research involving:

• Peripheral nerve injury
• Neuroinflammation
• Microglial signaling
• Neural repair
• Neuropathic pain mechanisms
• Neuroprotective signaling
• Tissue-injury responses

Importantly, experimental findings should not be interpreted as proof that ARA-290 is an established treatment.

ARA-290 and Tissue-Protection Research

ARA-290 is frequently described in the scientific literature as a non-erythropoietic EPO-derived peptide. Researchers developed this class of compounds to investigate tissue-protective signaling while avoiding the hematopoietic activity associated with conventional EPO. This makes ARA-290 useful for studying biological pathways involving:

• Cellular stress
• Tissue injury
• Inflammatory signaling
• Cellular survival
• Repair mechanisms
• Neurovascular biology
• Peptide-receptor interactions

ARA-290 and Neuropathy Research

ARA-290 has been studied in both experimental models and early human research involving neuropathy. A PubMed-indexed review reported that ARA-290 had been investigated in people with small-fiber neuropathy associated with sarcoidosis and type 2 diabetes. The review described changes in neuropathic and autonomic symptoms and reported experimental nerve-fiber findings, while emphasizing the need for additional clinical studies and longer-term follow-up. View the ARA-290 Neuropathy Review on PubMed A separate phase 2 study in people with type 2 diabetes investigated ARA-290 over 28 days and reported changes in neuropathic symptoms, HbA1c, lipid profiles, and corneal nerve-fiber measurements. The authors concluded that further clinical evaluation was warranted. Read the ARA-290 Phase 2 Study on PubMed

ARA-290 and Inflammation Research

Another important research area is inflammatory signaling. Experimental work has examined whether ARA-290 can influence inflammatory responses associated with nerve injury and autoimmune neuritis. In animal models, researchers observed changes involving inflammatory cells, Schwann cells, T-cell populations, and nerve regeneration. These findings make ARA-290 relevant to research involving:

• Neuroinflammation
• Immune-cell signaling
• Peripheral nerve inflammation
• Schwann-cell biology
• Tissue repair
• Autoimmune nerve models

ARA-290 Molecular Characteristics

Key characteristics of ARA-290 include:

• Also known as cibinetide
• Also known as pHBSP
• 11-amino-acid peptide
• Derived from the structural region of erythropoietin
• Non-erythropoietic EPO-derived peptide
• Investigated as an innate repair receptor agonist
• Studied in peripheral nerve and tissue-protection research

A published review describes ARA-290 as an 11-amino-acid linear peptide with a molecular weight of approximately 1,257 Da.

ARA-290 Research Applications

ARA-290 may be investigated in laboratory and scientific research involving:

• Innate repair receptor biology
• Neurobiology
• Peripheral nerve research
• Neuroinflammation
• Tissue-protection mechanisms
• Cellular signaling
• Immunology
• Schwann-cell research
• Nerve regeneration models
• Peptide pharmacology
• EPO-derived peptide research
• Molecular biology
• Tissue-injury models

Why Researchers Study ARA-290

ARA-290 provides researchers with a model for investigating tissue-protective receptor signaling without directly reproducing the classical erythropoietic effects of EPO. Its unique relationship with the IRR has made it particularly interesting for research into the interaction between inflammation, tissue injury, and repair. The scientific interest remains active. A 2024 review describes continued investigation of ARA-290 and related EPO-derived peptides while identifying peptide stability and short biological half-life as areas requiring further research.

Research Quality and Laboratory Handling

When purchasing ARA-290 for laboratory research, researchers should consider:

• Peptide identity
• Purity specifications
• Batch consistency
• Certificate of analysis
• Product documentation
• Packaging integrity
• Appropriate storage conditions
• Laboratory handling requirements

Researchers should follow the manufacturer’s documentation and their institution’s laboratory safety procedures.

Related Research Peptides

Researchers investigating different peptide categories can also explore: GHRP-2 Acetate – research compound for peptide and receptor studies. Adipotide – investigational compound for laboratory research. Gonadorelin Acetate 2mg – peptide research compound. HGH 191AA 10IU – compound used in growth-hormone-related laboratory research. Vitamin B12 10ml – biochemical research product. 5-Amino-1MQ 5mg × 10 Vials – compound for metabolic and cellular research.

Authoritative ARA-290 Research Resources

For high-quality external references, researchers can consult: PubMed – ARA-290 Research PubMed – ARA-290 and the Innate Repair Receptor PubMed – ARA-290 Phase 2 Research PubMed – 2024 Review of EPO-Derived Peptides and Peripheral Nerve Injury National Center for Biotechnology Information (NCBI) PubMed Central (PMC) These resources provide access to peer-reviewed research and biomedical literature rather than commercial health claims.

Frequently Asked Questions

What is ARA-290?

ARA-290, also known as cibinetide or pHBSP, is an investigational 11-amino-acid peptide derived from the structure of erythropoietin and studied for its interaction with the innate repair receptor.

What is ARA-290 researched for?

Research has investigated ARA-290 in tissue-protection, peripheral nerve, neuroinflammation, neuropathy, cellular signaling, and repair-related models.

Is ARA-290 the same as erythropoietin?

No. ARA-290 is an EPO-derived peptide designed to selectively interact with the innate repair receptor rather than functioning as conventional erythropoietin.

Is ARA-290 FDA approved?

ARA-290 should not be represented as an FDA-approved medication. Research and clinical investigations have evaluated its biological and potential therapeutic properties, but that does not establish regulatory approval.

Where can researchers find ARA-290 studies?

Researchers can find peer-reviewed ARA-290 research through PubMed and PubMed Central, including studies involving neuropathy, tissue protection, neuroinflammation, and peripheral nerve biology.

Important Research Disclaimer

ARA-290 is supplied exclusively for laboratory, analytical, and educational research purposes. It is not intended for human consumption, self-administration, veterinary use, diagnosis, treatment, cure, or prevention of any disease. The information on this page describes scientific research areas and should not be interpreted as medical advice or evidence of an approved therapeutic use. Research should be conducted by qualified professionals using appropriate laboratory safety procedures and applicable institutional requirements.